Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy

Ka Lai Yip; Michael Udoh; Laura A Sharman; Thomas Harman; Miguel Bedoya-Pérez; Lyndsey L Anderson; Samuel D Banister; Jonathon C Arnold

doi:10.1111/epi.18177

Cannabinoid-like compounds found in non-cannabis plants exhibit antiseizure activity in genetic mouse models of drug-resistant epilepsy

Epilepsia. 2024 Nov 12. doi: 10.1111/epi.18177. Online ahead of print.

Authors

Ka Lai Yip^{1

2

3}, Michael Udoh^{1

2

3}, Laura A Sharman^{1

2

3}, Thomas Harman^{1

2

3}, Miguel Bedoya-Pérez^{2

3

4}, Lyndsey L Anderson^{1

2

3}, Samuel D Banister^{2

3}, Jonathon C Arnold^{1

2

3}

Affiliations

¹ Discipline of Pharmacology, Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
² Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, New South Wales, Australia.
³ Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
⁴ School of Psychology, Faculty of Science, University of Sydney, Sydney, New South Wales, Australia.

PMID: 39530840
DOI: 10.1111/epi.18177

Abstract

Objective: The cannabinoid cannabidiol has established antiseizure effects in drug-resistant epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. Amorfrutin 2, honokiol, and magnolol are structurally similar to cannabinoids (cannabis-like drugs) but derive from non-cannabis plants. We aimed to study the antiseizure potential of these compounds in various mouse seizure models. In addition, we aimed to characterize their molecular pharmacology at cannabinoid CB₁ and CB₂ receptors and at T-type calcium channels, which are known targets of the cannabinoids.

Methods: Brain and plasma pharmacokinetic profiles were determined. Antiseizure activity was assessed against hyperthermia-induced seizures in a Scn1a^+/- mouse model of Dravet syndrome. We then elaborated on the most promising compounds in the maximal electroshock (MES) test in mice and the Gabrb3^+/D120N mouse model of Lennox-Gastaut syndrome. Fluorescence-based assays were used to examine modulatory activity at cannabinoid CB₁ and CB₂ receptors and T-type calcium channel subtypes Ca_V3.1, Ca_V3.2, and Ca_V3.3 overexpressed in mammalian cells. Automated patch-clamp electrophysiology was then used to confirm inhibitory activity on Ca_V3.1, Ca_V3.2, and Ca_V3.3 channels.

Results: Magnolol and honokiol had high brain-to-plasma ratios (3.55 and 7.56, respectively), unlike amorfrutin 2 (0.06). Amorfrutin 2 and magnolol but not honokiol significantly increased the body temperature threshold at which Scn1a^+/- mice had a generalized tonic-clonic seizure. Both amorfrutin 2 and magnolol significantly decreased the proportion of mice exhibiting hindlimb extension in the MES test. Furthermore, magnolol reduced the number and duration of atypical absence seizures in Gabrb3^+/D120N mice. The three compounds inhibited all T-type calcium channel subtypes but were without specific activity at cannabinoid receptors.

Significance: We show for the first time that amorfrutin 2 and magnolol display novel antiseizure activity in mouse drug-resistant epilepsy models. Our results justify future drug discovery campaigns around these structural scaffolds that aim to develop novel antiseizure drugs for intractable epilepsies.

Keywords: Dravet syndrome; Lennox–Gastaut syndrome; T‐type calcium channels; antiseizure drugs; cannabinoids; natural products.

Abstract

Grants and funding